Tempest Therapeutics, Inc. (TPST) stock
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.01 (-3.53%)
Close on Nov 12, 2026Market cap $5.67MP/E –Yield –
Earnings
Tempest Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
$0.34
-$2.07 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Tempest Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | – | – | $0.34 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | -$2.53 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | – | – | -$0.79 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025after the close | – | – | -$2.07 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025after the close | – | – | -$3.16 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | – | – | -$0.41 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | – | – | -$0.42 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$0.36 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 19, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | – | – | -$0.48 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$0.54 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | – | – | -$0.55 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | – | – | $0.66 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | – | – | -$0.79 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 13, 2022before the open | – | – | $1.18 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | – | – | $1.21 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Jan 13, 2020before the open | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Mar 29, 2019before the open | – | – | – | Filing |
| Q1 FY2018ended Mar 31, 2018 | May 3, 2018after the close | – | – | – | Filing |
| Q4 FY2017ended Dec 31, 2017 | Mar 15, 2018after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Tempest Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Tempest Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Tempest Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Update
- News
- Results
See a number that looks wrong?